Uli Hacksell is a veteran pharmaceutical executive and board chairman with deep expertise in CNS drug development. As the former CEO of ACADIA Pharmaceuticals, he was instrumental in the development of NUPLAZID®, a breakthrough treatment for Parkinsons disease psychosis. He earned his Ph. D. from Uppsala University in Sweden.
He is a highly respected scientist, having co-authored more than 170 scientific papers and holding numerous patents.
Uli Hacksell
CEO at ACADIA Pharmaceuticals
San Diego, California, United States
Overview
Topics They Care About
CNS Drug Development
His career has centered on creating novel therapeutics for central nervous system disorders, exemplified by his leadership in developing NUPLAZID at ACADIA Pharmaceuticals.
Biotech Board Governance
He currently serves as the Chairman of the Board for multiple biopharmaceutical companies, including Annexon Biosciences, indicating a focus on corporate strategy and oversight.
Neuroscience Research
With a background as a professor and over 170 co-authored scientific papers, he is deeply engaged in the underlying science of neuropharmacology.
Media Appearances
ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D.. Featured in Acadia Pharmaceuticals (official press release)
Work History
9-2000
CEO at ACADIA Pharmaceuticals
Education
Uli has no verified education history
More Information
Social Presence :
Prographics :
Exp : 25
Location : San Diego, California, United States
Job Level : Leadership
Designation : CEO at ACADIA Pharmaceuticals
